Get the Facts

Find what you need to know
in our brochures.


Get our
Press Kit

Official information for
articles and stories.


Multiple Myeloma News

Sort by Category:

Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma.

Reece DE, Trieu Y, Masih-Khan E, Atenafu EG, Chen C, Prica A, Tiedemann R, Trudel S, Kukreti V. Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):387-94. doi: 10.1016/j.clml.2016.04.012. Epub 2016 May 10. PMID: 27349765 [PubMed - in process] Read More

July 21, 2016

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.

Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. Lancet Haematol. 2016 Jul;3(7):e340-51. doi: 10.1016/S2352-3026(16)30049-7. PMID: 27374467 [PubMed - in process] Read More

July 21, 2016

Autologous stem cell transplant for multiple myeloma patients 70 years or older.

Muchtar E, Dingli D, Kumar S, Buadi FK, Dispenzieri A, Hayman SR, Wolf RC, Gastineau DA, Chakraborty R, Hogan WJ, Leung N, Kapoor P, Lacy MQ, Rajkumar SV, Gertz MA. Bone Marrow Transplant. 2016 Jul 4. doi: 10.1038/bmt.2016.174. [Epub ahead of print] PMID: 27376447 [PubMed - as supplied by publisher] Read More

July 21, 2016

Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma.

Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Leuk Lymphoma. 2016 Jul 7:1-8. [Epub ahead of print] PMID: 27390076 [PubMed - as supplied by publisher] Read More

July 21, 2016

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up a randomised, controlled, phase 3 trial.

Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, Corral LL, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Arguiñano JM, Quintana N, García JL, Bladé J, Lahuerta JJ, Miguel JS. Lancet Oncol. 2016 Jul 8. pii: S1470-2045(16)30124-3. doi: 10.1016/S1470-2045(16)30124-3. [Epub ahead of print] PMID: 27402145 [PubMed - as supplied by publisher] Read More

July 21, 2016

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma.

Liu L, Zhao N, Xu W, Sheng Z, Wang L. J Hematol Oncol. 2016 Jul 12;9(1):54. doi: 10.1186/s13045-016-0286-x. PMID: 27405295 [PubMed - in process] Free PMC Article Read More

July 21, 2016

Page 1 of 4512345...102030...Last »